Primary information |
---|
ID | 1349 |
Peptide Name | Formula 11 |
Sequence | [RKDV-NH-CH2]2 |
Length | 8 |
Chirality | L |
N-terminal Modification | None |
C-terminal Modification | None |
Chemical Modification | None |
Linear/ Cyclic | Linear |
Nature | Synthetic |
Source of Origin | NA |
Target | Suppress the antigen presentation of macrophages or antigen recognition of T-cells in the immune processes |
Mechanism of Action | Inhibit maturation of the T-cell dependent antibody producing cells, supress the phagocytosis and dminish the late hypersensitive response |
In vitro/In vivo | In vitro |
Cell Line | Splenocyte s obtained from rats |
Inhibition Concentartion | NA |
In vivo Model | Twelve Wistar (LATI) rats |
Assay | Hummoral Immune Response assay |
Lethal Dose | NA |
Combination Therapy | NA |
Pubmed ID | US 5093320 |
Year of Publication | 1992 |
3-D Structure | NA |